{"title":"氢醌乳膏与氢醌乳膏加当归芍药散治疗黄褐斑的疗效比较。","authors":"Yuan-Yuan Cheng, Rui-Rui Peng, Hao Luo, Wei Zhao","doi":"10.5114/ada.2023.135613","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Melasma is an acquired hypermelanosis and occurs in areas exposed to sunlight.</p><p><strong>Aim: </strong>To investigate the effectiveness of Danggui Shaoyao powder (DSP) as a complementary drug in the treatment of melasma.</p><p><strong>Material and methods: </strong>A total of 40 melasma patients over the age of 18 who met the inclusion criteria entered the study randomly in two DSP + Hydroquinone (DSP + H) and Hydroquinone (H) groups.</p><p><strong>Results: </strong>At the beginning of the study, the average MASI score of the two groups of patients had no statistical difference (DSP + H: 15.79 ±1.01 vs. H: 15.37 ±1.17, <i>p</i> = 0.23). But from the eighth week of treatment, the MASI score of the patients decreased significantly and in the DSP + H group it decreased statistically significantly compared to the H group (DSP + H: 5.83 ±0.97 vs. H: 8.29 ±2.23, <i>p</i> < 0.001 for the eighth week and DSP + H: 3.60 ±0.58 vs. H: 5.52 ±1.73, <i>p</i> < 0.001 for the twelfth week of the treatment). It means after 12 weeks of treatment, the average MASI score of patients in the DSP + H group decreased by 77.26 ±2.70%, but in the grroup H, it decreased by 64.31 ±9.68% (<i>p</i> < 0.001). Dynamic PGA showed that excellent treatment occurred in 65% of the + H group H, but only 20% of the H group (<i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>Oral DSP for 12 weeks along with hydroquinone cream can significantly reduce the MASI score of melasma patients and increase the patients' recovery and satisfaction.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"41 1","pages":"66-71"},"PeriodicalIF":1.4000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962367/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of the efficacy of Hydroquinone cream versus Hydroquinone cream plus Danggui Shaoyao powder in the treatment of melasma.\",\"authors\":\"Yuan-Yuan Cheng, Rui-Rui Peng, Hao Luo, Wei Zhao\",\"doi\":\"10.5114/ada.2023.135613\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Melasma is an acquired hypermelanosis and occurs in areas exposed to sunlight.</p><p><strong>Aim: </strong>To investigate the effectiveness of Danggui Shaoyao powder (DSP) as a complementary drug in the treatment of melasma.</p><p><strong>Material and methods: </strong>A total of 40 melasma patients over the age of 18 who met the inclusion criteria entered the study randomly in two DSP + Hydroquinone (DSP + H) and Hydroquinone (H) groups.</p><p><strong>Results: </strong>At the beginning of the study, the average MASI score of the two groups of patients had no statistical difference (DSP + H: 15.79 ±1.01 vs. H: 15.37 ±1.17, <i>p</i> = 0.23). But from the eighth week of treatment, the MASI score of the patients decreased significantly and in the DSP + H group it decreased statistically significantly compared to the H group (DSP + H: 5.83 ±0.97 vs. H: 8.29 ±2.23, <i>p</i> < 0.001 for the eighth week and DSP + H: 3.60 ±0.58 vs. H: 5.52 ±1.73, <i>p</i> < 0.001 for the twelfth week of the treatment). It means after 12 weeks of treatment, the average MASI score of patients in the DSP + H group decreased by 77.26 ±2.70%, but in the grroup H, it decreased by 64.31 ±9.68% (<i>p</i> < 0.001). Dynamic PGA showed that excellent treatment occurred in 65% of the + H group H, but only 20% of the H group (<i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>Oral DSP for 12 weeks along with hydroquinone cream can significantly reduce the MASI score of melasma patients and increase the patients' recovery and satisfaction.</p>\",\"PeriodicalId\":54595,\"journal\":{\"name\":\"Postepy Dermatologii I Alergologii\",\"volume\":\"41 1\",\"pages\":\"66-71\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10962367/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Postepy Dermatologii I Alergologii\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5114/ada.2023.135613\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/2/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2023.135613","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/28 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
摘要
简介黄褐斑是一种后天性黑素沉着症,多发于暴露于阳光下的部位。目的:研究当归芍药散(DSP)作为辅助药物治疗黄褐斑的效果:符合纳入标准的18岁以上黄褐斑患者共40名,随机分为DSP+氢醌(DSP+H)和氢醌(H)两组:研究开始时,两组患者的平均MASI评分无统计学差异(DSP + H:15.79 ±1.01 vs. H:15.37 ±1.17,p = 0.23)。但从治疗的第八周开始,患者的 MASI 评分明显下降,DSP + H 组的 MASI 评分与 H 组相比有显著的统计学下降(第八周 DSP + H:5.83 ±0.97 vs. H:8.29 ±2.23,p < 0.001;第十二周 DSP + H:3.60 ±0.58 vs. H:5.52 ±1.73,p < 0.001)。这意味着治疗 12 周后,DSP + H 组患者的 MASI 平均得分下降了 77.26 ±2.70% ,而 H 组则下降了 64.31 ±9.68% (P < 0.001)。动态 PGA 显示,65% 的 + H 组 H 患者治疗效果极佳,但只有 20% 的 H 组 H 患者治疗效果极佳(p = 0.01):结论:口服 DSP 12 周,同时使用氢醌乳膏可显著降低黄褐斑患者的 MASI 评分,提高患者的康复率和满意度。
Comparison of the efficacy of Hydroquinone cream versus Hydroquinone cream plus Danggui Shaoyao powder in the treatment of melasma.
Introduction: Melasma is an acquired hypermelanosis and occurs in areas exposed to sunlight.
Aim: To investigate the effectiveness of Danggui Shaoyao powder (DSP) as a complementary drug in the treatment of melasma.
Material and methods: A total of 40 melasma patients over the age of 18 who met the inclusion criteria entered the study randomly in two DSP + Hydroquinone (DSP + H) and Hydroquinone (H) groups.
Results: At the beginning of the study, the average MASI score of the two groups of patients had no statistical difference (DSP + H: 15.79 ±1.01 vs. H: 15.37 ±1.17, p = 0.23). But from the eighth week of treatment, the MASI score of the patients decreased significantly and in the DSP + H group it decreased statistically significantly compared to the H group (DSP + H: 5.83 ±0.97 vs. H: 8.29 ±2.23, p < 0.001 for the eighth week and DSP + H: 3.60 ±0.58 vs. H: 5.52 ±1.73, p < 0.001 for the twelfth week of the treatment). It means after 12 weeks of treatment, the average MASI score of patients in the DSP + H group decreased by 77.26 ±2.70%, but in the grroup H, it decreased by 64.31 ±9.68% (p < 0.001). Dynamic PGA showed that excellent treatment occurred in 65% of the + H group H, but only 20% of the H group (p = 0.01).
Conclusions: Oral DSP for 12 weeks along with hydroquinone cream can significantly reduce the MASI score of melasma patients and increase the patients' recovery and satisfaction.